Phio Pharmaceuticals CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Phio Pharmaceuticals reports promising early clinical data for PH-762 and significant capital raises in 2025, extending its operational runway.
NASDAQ
Phio Pharmaceuticals Corp. files its 10-K report for the fiscal year ended December 31, 2024, detailing financial results and progress in its clinical-stage immuno-oncology programs, particularly the Phase 1b trial of PH-762.
NASDAQ
Phio Pharmaceuticals Corp.'s 10-K filing outlines the company's share structure, voting rights, and anti-takeover provisions, while also detailing recent financial activities and strategic shifts.